Rx (Prescription Medicine)
USD $ 433.00
Bevnexxa 100mg 注射液是一种靶向疗法，用于治疗某些类型的癌症。其活性成分为bevacizumab，是一种重组人源化单克隆抗体，可抑制血管内皮生长因子（VEGF）。通过阻断VEGF，Bevnexxa有助于减少肿瘤的血供，从而减缓或停止其生长。它通常与化疗联合使用，用于转移性结直肠癌、非小细胞肺癌和胶质母细胞瘤。Bevnexxa 100mg 注射液通过静脉给药，需由医护专业人员操作。患者应告知医生任何既往病史，尤其是心脏病、高血压或出血性疾病史，因为这些情况可能影响治疗。潜在的不良反应包括高血压、蛋白尿和伤口愈合延迟。请将注射液储存于室温并避光保存，勿冷冻。
| Medicine Form | |
|---|---|
| Rx Status | |
| Medicine Type | |
| Brand Name | |
| Molecule | |
| Strength | 100 Mg |
| Medicine Form | Injection |
| Pack Quantity | 1 Vial |
| Packaging Type | Vial |
| Medicine Type | Generic |
| Country Of Origin | India |
| Rx Status | Rx (Prescription Medicine) |
其他品牌的 Bevacizumab 100 Mg — 同一活性成分且强度相同，但来自不同制造商。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
